



For immediate release January 31, 2020

## **Genovis AB (publ) to publish 2020 reports ahead of schedule**

**The Board of Directors of Genovis AB (publ) has decided to publish Q1- Q3 2020 reports ahead of schedule due to more efficient financial routines.**

### **The new publication dates for the reports 2020 are:**

Year-end Report	January 1 – December 31, 2019	February 5
Interim Report	January 1 – March 31, 2020	April 29
Half-Yearly Report	January 1 – June 30, 2020	August 13
Interim report	January 1 – September 30, 2020	November 5

### **For more information, please contact:**

Fredrik Olsson, CEO, Genovis AB

T: +46 (0)46-12 12 33

E: fredrik.olsson@genovis.com

### **ABOUT GENOVIS**

Genovis' business concept is to apply its knowledge and imagination to design and provide innovative tools for development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes™ all over the world in innovative product formats that facilitate development and quality control of biological drugs.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (US). Genovis' shares are listed on NASDAQ First North Stockholm and Erik Penser Bank is the Company's Certified Adviser, certifiedadviser@penser.se, tel: +46 (0)8-463 83 00.

*This is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.*